The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Jan. 08, 2019
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventor:

Marco L. Davila, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/725 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); C07K 14/7051 (2013.01); A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

Disclosed are compositions and methods for targeted treatment of CLEC12A-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CLEC12A-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CLEC12A-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CLEC12A-expressing malignant cells.


Find Patent Forward Citations

Loading…